Drug intelligence / Profile preview

GH peptide

Development stage: Preclinical
Lead developer: Sun Yat-sen University
Modality: Peptides
Administration: Intravenous

Overview

GH peptide is an antagonistic peptide that specifically binds to the first extracellular loop of the C-C chemokine receptor type 5 (CCR5). It has been investigated in preclinical studies using a murine model of asthma, where it demonstrated a significant reduction in allergic inflammation, mucus secretion, and the expression of key inflammatory markers such as IL-23p19, IL-23R, IL-17A, and lactoferrin (LTF). Its mechanism of action involves inhibiting the CCR5-mediated IL-23/T helper 17 (Th17) signaling pathway, thereby alleviating airway inflammation. The peptide was chemically synthesized by GL Biochem Co., Ltd. and studied in the context of asthma.

Other names: antagonistic peptide that specifically binds to the first extracellular loop of CCR5

Targets

CCR5 (C-C chemokine receptor type 5)

Beyond the preview

Go deeper on GH peptide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GH peptide.

Explore the full profile